Research-led nutrition, recovery, and longevity coverage with a quieter visual language and clearer hierarchy.
Peptides, recovery protocols, and practical interpretation.
Better pacing, less filler, and just enough imagery to support the text.
Retatrutide is a triple agonist peptide by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors — producing up to 24.2% body weight loss in Phase 2 trials. Here's everything you need to know about how it works, how it compares to semaglutide and tirzepatide, and where it stands in 2026.
Structure, tone, and scientific discipline matter as much as topic choice.
Retatrutide is a triple agonist peptide by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors — producing up to 24.2% body weight loss in Phase 2 trials. Here's everything you need to know about how it works, how it compares to semaglutide and tirzepatide, and where it stands in 2026.
Retatrutide side effects are mostly gastrointestinal — nausea, vomiting, and stomach discomfort top the list. This guide covers what to expect at each dose level, TRIUMPH trial data, women-specific effects, and practical strategies for managing symptoms.
Join practitioners and readers who want concise breakdowns, cleaner design, and stronger curation.
What Is Retatrutide? The Triple Agonist Explained